BR112022011127A2 - Composto agonista do receptor de detecção de cálcio e aplicação do mesmo - Google Patents

Composto agonista do receptor de detecção de cálcio e aplicação do mesmo

Info

Publication number
BR112022011127A2
BR112022011127A2 BR112022011127A BR112022011127A BR112022011127A2 BR 112022011127 A2 BR112022011127 A2 BR 112022011127A2 BR 112022011127 A BR112022011127 A BR 112022011127A BR 112022011127 A BR112022011127 A BR 112022011127A BR 112022011127 A2 BR112022011127 A2 BR 112022011127A2
Authority
BR
Brazil
Prior art keywords
application
agonist compound
receptor agonist
calcium
agonist
Prior art date
Application number
BR112022011127A
Other languages
English (en)
Portuguese (pt)
Inventor
Wu Fangzhou
Zhang Jin
Gao Fei
Wu Ran
Liao Cheng
Wang Lei
Original Assignee
Beijing Tuo Jie Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tuo Jie Biopharmaceutical Co Ltd filed Critical Beijing Tuo Jie Biopharmaceutical Co Ltd
Publication of BR112022011127A2 publication Critical patent/BR112022011127A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112022011127A 2019-12-09 2020-12-08 Composto agonista do receptor de detecção de cálcio e aplicação do mesmo BR112022011127A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911250088 2019-12-09
PCT/CN2020/134598 WO2021115272A1 (zh) 2019-12-09 2020-12-08 钙敏感受体激动剂化合物及其应用

Publications (1)

Publication Number Publication Date
BR112022011127A2 true BR112022011127A2 (pt) 2022-08-23

Family

ID=76328843

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011127A BR112022011127A2 (pt) 2019-12-09 2020-12-08 Composto agonista do receptor de detecção de cálcio e aplicação do mesmo

Country Status (11)

Country Link
US (1) US20230041996A1 (cg-RX-API-DMAC7.html)
EP (1) EP4091623A4 (cg-RX-API-DMAC7.html)
JP (1) JP7796013B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220110789A (cg-RX-API-DMAC7.html)
CN (2) CN118496313A (cg-RX-API-DMAC7.html)
AU (1) AU2020399030B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022011127A2 (cg-RX-API-DMAC7.html)
CA (1) CA3159744A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006892A (cg-RX-API-DMAC7.html)
TW (1) TW202122410A (cg-RX-API-DMAC7.html)
WO (1) WO2021115272A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117295510A (zh) * 2021-06-08 2023-12-26 北京拓界生物医药科技有限公司 一种钙敏感受体激动剂的组合物及其应用
TW202313655A (zh) * 2021-06-08 2023-04-01 大陸商北京拓界生物醫藥科技有限公司 鈣敏感受體激動劑化合物的鹽酸鹽及醫藥組成物和其應用
CN121378400A (zh) * 2024-10-24 2026-01-23 成都诺和晟泰生物科技有限公司 一种多肽化合物、包含其的组合物及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050460A1 (es) * 2003-04-23 2005-07-08 Japan Tobacco Inc COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
EP2459208B1 (en) * 2009-07-29 2016-09-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
CN103270018A (zh) * 2010-11-26 2013-08-28 利奥制药有限公司 钙敏感受体激活化合物
WO2012069421A1 (en) * 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
PT2717896T (pt) * 2011-06-08 2016-12-23 Kai Pharmaceuticals Inc Agentes terapêuticos para a regulação do fósforo sérico
MX355063B (es) * 2011-11-10 2018-04-04 Kai Pharmaceuticals Inc Calcimiméticos y métodos para su uso.

Also Published As

Publication number Publication date
US20230041996A1 (en) 2023-02-09
AU2020399030A1 (en) 2022-06-23
KR20220110789A (ko) 2022-08-09
EP4091623A1 (en) 2022-11-23
CN114222578B (zh) 2024-06-25
CN118496313A (zh) 2024-08-16
TW202122410A (zh) 2021-06-16
EP4091623A4 (en) 2024-01-03
CA3159744A1 (en) 2021-06-17
MX2022006892A (es) 2022-10-07
WO2021115272A1 (zh) 2021-06-17
CN114222578A (zh) 2022-03-22
JP7796013B2 (ja) 2026-01-08
AU2020399030B2 (en) 2026-04-09
JP2023504904A (ja) 2023-02-07

Similar Documents

Publication Publication Date Title
CL2021003017S1 (es) Porción de dispositivo para administración de dosis. (divisional solicitud 200003174)
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
BR112016028818A2 (pt) composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo.
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
BR112017014067A2 (pt) composição para tratar doenças relacionadas a il-6
CL2018002009A1 (es) Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras.
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
MX2018001193A (es) Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos.
BR112015027114A2 (pt) novos compostos para os inibidores seletivos de histona desacetilase, e composição farmacêutica compreendendo os mesmos
BR112020005841A8 (pt) Peptídeo coagonista do receptor de gcg/glp-1, composição, método para tratar um paciente de uma doença ou distúrbio metabólico, e, uso de um ou mais peptídeos coagonistas.
BR112016028814A2 (pt) ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo?
BR112019003504A2 (pt) compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos
BR112022000956A2 (pt) Métodos de tratamento da hiperplasia adrenal congênita
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
BR112016029067A2 (pt) ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios?
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
BR112015022092A2 (pt) derivado de di-hidropiridazina-3,5-diona
MX2022006892A (es) Compuesto agonista del receptor sensor de calcio y aplicación del mismo.
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
EA202090900A1 (ru) Ингибиторы иммунопротеасом
BR112018010155A2 (pt) segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca
BR112017028616A2 (pt) acentuador de inibidores de homólogo de zeste 2
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
BR112016029065A2 (pt) ?composto, composição farmacêutica, e, uso de um composto?
BR112021024116A2 (pt) Composto bicíclico como inibidor de rip-1 quinase e aplicação do mesmo